Latest Us Market Growth News

Firebrick Pharma secured regulatory approval for Nasodine Nasal Spray in Indonesia and launched Nasodine Throat Spray in Singapore and Fiji, while raising $1.5 million to fuel growth. The company aims to quadruple its product and market footprint within three years.

Zip Co reported a 41.5% jump in third quarter cash EBTDA to $65.1 million, driven by accelerated US transaction volume growth of 43.1% and steady credit losses. The company upgraded its FY26 cash EBTDA guidance to at least $260 million, highlighting robust profitability and expanding customer engagement.

ImpediMed Limited has appointed Erik Anderson as its new CEO and Managing Director, effective 7 April 2026, aiming to boost commercial execution and revenue growth in the US market. Dr Parmjot Bains will remain as an advisor until 30 June 2026 to ensure a smooth leadership transition.

Bubs Australia has delivered a robust first half for FY26, powered by a 48% revenue surge in the US, prompting an upgrade to its full-year earnings guidance.

Perenti Limited reported steady half-year revenue of $1.73 billion with a 10.9% increase in net profit, underpinned by a $300 million Dalgaranga contract and growing drilling services in the US. The company also announced an unfranked interim dividend and a CEO transition underway.

Xero Limited has outlined a bold AI strategy and detailed the integration of Melio to accelerate its US market growth, supported by new financial disclosures and a clear path to profitability.

The Calmer Co has posted a record $2.01 million in sales for Q2 FY26, propelled by a 9% increase in US revenue which now accounts for over half of the group’s total income. Strong retail and wholesale growth underpin the company’s expanding footprint in the natural relaxation market.

Nova Eye Medical has reported a record US$6.1 million in global sales for the December 2025 quarter, marking a 38% year-on-year increase and strong momentum across key markets. The company’s innovative iTrack™ technology continues to drive growth, supported by expanded manufacturing capacity and advancing clinical programs.

Adveritas Limited has reported a record $14.25 million annualised recurring revenue for the December 2025 quarter, driven by strong US market growth and AI-enhanced product development. The company’s strategic focus on media agency partnerships and new product lines signals robust momentum ahead.

Lumos Diagnostics has achieved a major milestone by securing 100% Medicare reimbursement recognition for its FebriDx test across all seven US Medicare Administrative Contractors, paving the way for broader adoption in the American healthcare system.

MedAdvisor Limited has appointed John Ciccio as its new CEO and Managing Director, marking a strategic leadership shift aimed at capitalising on recent technology advancements and US market growth.

Adherium Limited reports a strong quarter with a 55% increase in device shipments and groundbreaking clinical results from its iCARE study, alongside securing over $2.6 million in post-quarter funding.